Abeona Therapeutics CFO sells $110k in stock

Joseph Walter Vazzano, Chief Financial Officer of Abeona Therapeutics INC (NASDAQ:ABEO), sold 15,000 shares of common stock on August 15, 2025. The sales were executed at weighted average prices ranging from $7.20 to $7.48, resulting in total proceeds of $110,358. The timing is notable as the stock has gained 15.5% in the past week and is trading near its 52-week high of $7.32. InvestingPro analysis indicates the stock is currently overbought, one of several key insights available to subscribers.

Following the transaction, Vazzano directly owns 462,666 shares of Abeona Therapeutics.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.48 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

In other recent news, Abeona Therapeutics reported an unexpected profit for Q2 2025, surprising investors and analysts alike. The company announced earnings per share of $1.71, a significant deviation from the anticipated loss of $0.38 per share, resulting in a 550% earnings surprise. Revenue for the quarter reached $400,000, surpassing forecasts that had not anticipated any revenue. This marks a notable development for Abeona Therapeutics, as the company continues to navigate its financial landscape. The earnings announcement has sparked interest in the company’s future performance. Analyst reactions to these results are yet to be fully detailed, but the earnings surprise might influence future evaluations. Investors are closely watching how Abeona Therapeutics will sustain this unexpected financial performance in the coming quarters.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.